Quotient Clinical, a business unit of Quotient Bioresearch, has completed a major expansion of its clinical facilities in Nottingham, UK. The expansion includes a 50% increase in bed capacity and a dedicated sample processing lab for human ADME studies. The new facilities have been inspected and approved for use by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), and have been awarded Supplementary Accreditation.

The facilities will operate under Quotient’s Synthesis-to-Clinic platform in support of human ADME studies, reinforcing the company’s provision of 14C-enabled drug development services including Phase 0 microdose, ivMicrotracer, and human metabolism studies.

Mark Egerton, M.D. of Quotient Clinical, said,“In parallel with the recent expansion of our Pharmaceutical Sciences laboratory and GMP drug product manufacturing facility, the completion of this clinical expansion is another milestone in the development of our business. It underlines the strength of our Synthesis-to-Clinic platform and the benefits it brings to our global client base. Our expanded facilities will assist the continued development of our services, supporting our customers in taking new and innovative approaches in early drug development.”